Thrombophilia or hypercoagulability is a condition in which the blood cell coagulation rate increases, leading to thrombosis. It occurs due to abnormalities in blood such as increase in red blood cells (polycythemia) or increase in platelets (thrombocytosis or thrombocythemia). There are two types of Thrombophilia i.e. Inherited type and Acquired type. Inherited type of Thrombophilia occur due to abnormalities of the genes which leads the coagulation proteins (known as genetic mutations). The inherited thrombophilia include Factor V Leiden (specific gene), deficiencies of Protein C, Protein S, Prothrombin gene mutations and Prothrombin gene variant 20210A. The acquired thrombophilia occurs due to abnormal clotting of the blood cells or special proteins which may also lead to clotting. The acquired thrombophilia occurs during surgery, injury, or medical conditions such as congestive heart failure and certain respiratory conditions which are called as Antiphospholipid antibodies. The coagulation testing are carried out to identify the clots in blood vessel. There are several coagulation tests are carried out for identifying the thrombophilia such as complete blood count, Factor V assay, bleeding time, thrombin time, and platelet count and fibrinogen level. Thrombophilia testing is also used inappropriately to decide about primary or secondary thromboprophylaxis.
Thrombophilia Testing Market: Drivers and Restraints
The advance technologies used for thrombophilia testing and increasing aging population across the world are major drivers for thrombophilia testing market. The various government associations have taken initiatives to raise awareness through events about various blood disorders that may leads to thrombophilia testing. The poor reimbursement policies provided by government and cost and high cost of treatment in many developing countries across the world are expected to hinder the growth considerably for thrombophilia testing Market.
Download sample copy of this report:
Thrombophilia Testing Market: Overview
The global market for thrombophilia testing is estimated to experience a significant growth during the forecast period. The increase in the aging population, increasing occurrence of rare and chronic diseases will create a more lucrative opportunity for thrombophilia testing in the forecast period. The thrombophilia testing include set of tests such as Factor V Assay, Prothrombin Time (PT or PT-INR). Fibrinogen Level, Complete Blood Count (CBC), Platelet Count, Thrombin Time, Bleeding Time.
Thrombophilia Testing Market: Regional Wise Outlook
On the basis of geography, the thrombophilia testing market is classified into seven regions viz. South Asia, East Asia, Europe, Latin America, North America, Oceania and Middle East and Africa. The North America and European Union are anticipated the major region for the thrombophilia testing. East and South Asia Pacific region are developing economically and increasing their investment in healthcare system which may helpful for thrombophilia testing. Advanced or emerging healthcare settings help in restoring the market and increase the reach to a wider section of patients in need. In North America and Europe region are major reason due to their early adoption of advanced technology, high health care expenditure, increasing government initiatives for research and development activities estimated to have a significant share in the thrombophilia testing market, owing to its quality infrastructure supporting the need of thrombophilia testing.
Download Data Set @
The market of thrombophilia testing include Siemens Healthineers (Europe), Accriva Diagnostics (U.S.A.), Instrumentation Laboratory (U.S.), HomoSonics LLC. (U.S.), Sienco, Inc. (U.S.), Alere Inc. (U.S.). The present market structure of thrombophilia testing is expected to change with efforts and research present in clinical diagnosis.